Greg Reyes, M.D., Ph.D. has over 30 years of experience as a senior leader in biotech and large pharma exploring drug discovery and development in multiple therapy areas.   His leadership positions included leading Drug Discovery for Celgene Corporation and site head for their San Diego Calif facility (now part of Bristol-Myers Squibb) and prior to that leading the Oncology franchise at Biogen Idec (now Biogen). His resume also includes heading Discovery Biology at the Ann Arbor campus for Pfizer Inc. and leading the Tumor Biology and Infectious Diseases group at Schering-Plough (now Merck). Over the years his teams have nominated and progressed well over 50 compounds, both small molecules and biologics, from discovery into preclinical and clinical development.  One of those compounds, developed under his leadership at Schering-Plough, was Victrelis™ (boceprevir) which gained approval as one of the first antiviral treatments for chronic hepatitis C.  This seminal work to discover the first HCV protease inhibitor led to the 2012 Prix Galien Award shared by Victrelis™ and Vertex’s Incivek™ as the ‘best pharmaceutical agent’ in both the UK and US.

Greg obtained his M.D. and Ph.D. (Pharmacology and Experimental Therapeutics Department) degrees from The Johns Hopkins School of Medicine, Baltimore, MD, followed by medical training at Stanford University Hospital, Palo Alto, CA and a Damon Runyon Cancer Research Fellowship with the late Dr. Henry Kaplan at his Cancer Biology Research Lab, Stanford School of Medicine.  He has nearly 100 scientific publications and 50 US and foreign patents and patent applications. He currently serves as an advisor to the New Agents Committee of the Cancer Research UK (CRUK) organization and is past member of a number of senior advisory councils including the National Advisory General Medical Sciences (NAGMS) Council (National Institutes of Health), Past Chair of the External Advisory Committee to the International Outreach Program (St. Jude Children’s Research Hospital) and past member of the Standing Review Committee for the Research Centers in Minority Institutions, National Center for Research Resources (National Institutes of Health).